- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Mirada recruits German hospital
University Hospital Essen has signed an agreement with Mirada Solutions, a unit of CTI Molecular Imaging, to serve as the company's first European clinical reference site. German physicians will use Mirada software in a combined PET/CT environment to
University Hospital Essen has signed an agreement with Mirada Solutions, a unit of CTI Molecular Imaging, to serve as the company's first European clinical reference site. German physicians will use Mirada software in a combined PET/CT environment to address software fusion requirements as a complement to conventional hardware-based techniques. The hospital has been working with PET/CT imaging since October 2001. The collaboration is the first step toward establishing R&D partnerships among leading European institutions, CTI, and its subsidiaries, including Mirada Solutions and PETNET Pharmaceuticals. Mirada joined CTI Aug. 18, when CTI purchased all of Mirada's capital stock.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
